Cerevel Therapeutics (NASDAQ:CERE – Get Free Report) and JanOne (NASDAQ:JAN – Get Free Report) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, analyst recommendations, earnings, risk, valuation, profitability and institutional ownership.
Profitability
This table compares Cerevel Therapeutics and JanOne’s net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
Cerevel Therapeutics | N/A | -98.94% | -45.07% |
JanOne | N/A | -359.71% | -70.26% |
Analyst Recommendations
This is a summary of current recommendations for Cerevel Therapeutics and JanOne, as provided by MarketBeat.com.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Cerevel Therapeutics | 0 | 7 | 1 | 0 | 2.13 |
JanOne | 0 | 0 | 0 | 0 | N/A |
Insider & Institutional Ownership
87.7% of Cerevel Therapeutics shares are owned by institutional investors. Comparatively, 6.3% of JanOne shares are owned by institutional investors. 5.1% of Cerevel Therapeutics shares are owned by insiders. Comparatively, 3.0% of JanOne shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Earnings and Valuation
This table compares Cerevel Therapeutics and JanOne’s gross revenue, earnings per share and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Cerevel Therapeutics | N/A | N/A | -$432.84 million | ($2.73) | -16.47 |
JanOne | $39.61 million | 0.00 | -$7.81 million | N/A | N/A |
JanOne has higher revenue and earnings than Cerevel Therapeutics.
Volatility and Risk
Cerevel Therapeutics has a beta of 1.4, indicating that its stock price is 40% more volatile than the S&P 500. Comparatively, JanOne has a beta of 2.16, indicating that its stock price is 116% more volatile than the S&P 500.
Summary
Cerevel Therapeutics beats JanOne on 5 of the 8 factors compared between the two stocks.
About Cerevel Therapeutics
Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, develops various therapies for neuroscience diseases in the United States. It is developing Emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-concept trial in patients with drug-resistant focal onset seizures or focal epilepsy, as well as in phase 1 trial to treat panic symptoms model. The company's products also comprise Tavapadon, a selective dopamine D1/D5 partial agonist that is in phase 3 clinical trial for the treatment of early- and late-stage Parkinson's disease; CVL-871, a selective dopamine D1/D5 partial agonist, which is in Phase 2a clinical trial to treat dementia-related apathy; and CVL-354, a selective kappa-opioid receptor antagonist to treat major depressive disorder and substance use disorder. It is also involved in the development of an M4 agonist program for the treatment of psychosis and related indications; and PDE4 inhibitor for the treatment of psychiatric, neuroinflammatory, and other disorders. Cerevel Therapeutics Holdings, Inc. was founded in 2018 and is headquartered in Cambridge, Massachusetts.
About JanOne
JanOne Inc., a clinical-stage biopharmaceutical company, focuses on identifying, acquiring, licensing, developing, partnering, and commercializing novel, non-opioid, and non-addictive therapies to address the unmet medical need for the treatment of pain and addiction. It operates through Biotechnology and Recycling segments. The company's lead product candidate is JAN101, a patented oral and sustained release pharmaceutical composition of sodium nitrite that targets poor blood flow to the extremities in patients with diabetes or peripheral artery disease to treat pain. It also provides turnkey appliance recycling and replacement services for utilities and other sponsors of energy efficiency programs. The company was formerly known as Appliance Recycling Centers of America, Inc. and changed its name to JanOne Inc. in September 2019. JanOne Inc. was founded in 1976 and is headquartered in Las Vegas, Nevada.
Receive News & Ratings for Cerevel Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerevel Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.